Browse AMR Genes
Explore antimicrobial resistance genes from the literature
Explore antimicrobial resistance genes from the literature
multidrug resistance protein 7
Overview
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
Lapatinib and erlotinib reverse MRP7-mediated multidrug resistance by inhibiting the efflux function of MRP7, enhancing the intracellular accumulation of chemotherapeutic agents such as docetaxel, paclitaxel, vinblastine, and vinorelbine.
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).
Imatinib and nilotinib reverse MRP7-mediated multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 transporter.
PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
Sildenafil and vardenafil reverse MRP7-mediated multidrug resistance by inhibiting the efflux function of MRP7, enhancing the sensitivity of MRP7-transfected cells to paclitaxel, docetaxel, and vinblastine.
Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.
Tariquidar reverses MRP7-mediated multidrug resistance by inhibiting MRP7 protein expression and function, increasing the sensitivity of MRP7-expressing cells to anticancer drugs such as paclitaxel, docetaxel, vincristine, vinblastine, and vinorelbine.
bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10).
BBA reverses MRP7-mediated multidrug resistance by inhibiting the efflux function of MRP7 without affecting the intracellular ATP levels.
No comments yet. Be the first to comment!
© 2026 ResLit. Data sourced from PubMed literature analysis.
Built for antimicrobial resistance research